CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

This webinar explains how CAR-T cells transfected using Solupore® technology from Avectas and sorted using the CGX10 Cell Isolation System from Sony Biotechnology outperform unsorted cells in ...

Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over ...

By Vijay Kumar Malesu A pioneering personalized mRNA vaccine study reveals lasting immune responses in triple-negative breast cancer, offering early signals that tailored cancer vaccination may help ...

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.

As the trained killers of the immune system, cytotoxic T cells silently save our lives every day—vanquishing viruses before they can run amok, and putting nascent cancer cells out of business before ...

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

Balancing the immune system is a delicate act. If it’s too weak, infections and cancer can take hold; if it’s too strong, autoimmune diseases or transplant rejection can occur. Researchers have ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...